Aspirin and Mortality in Patients With Diabetes Sustaining Acute Coronary Syndrome
- Richard M. Cubbon, MBCHB1,
- Christopher P. Gale, PHD1,
- Adil Rajwani, MBCHB1,
- Afroze Abbas, MBCHB1,
- Christine Morrell, RGNSCM2,
- Raj Das, MD2,
- Julian H. Barth, MD3,
- Peter J. Grant, MD1,
- Mark T. Kearney, MD1 and
- Alistair S. Hall, PHD2
- 1Leeds Institute of Genetics, Health & Therapeutics, LIGHT Laboratories, University of Leeds, Leeds, U.K
- 2British Heart Foundation Heart Research Centre, Jubilee Wing, Leeds General Infirmary, Leeds, U.K
- 3Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds, U.K
- Address correspondence and reprint requests to Mark T. Kearney, Leeds Institute of Genetics, Health & Therapeutics, LIGHT Laboratories, University of Leeds, Clarendon Way, Leeds, LS2 9JT, U.K. E-mail: m.t.kearney{at}leeds.ac.uk
Abstract
OBJECTIVE—We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS).
RESEARCH DESIGN AND METHODS—We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes.
RESULTS—Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50–1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use.
CONCLUSIONS—Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 24 October 2007. DOI: 10.2337/dc07-1745.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted October 17, 2007.
- Received September 4, 2007.
- DIABETES CARE
